Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615904 | 0.81 | USP2 (0.39) | ALDH1A1HTTHPGDUSP2SMN1; SMN2 | |
| SCHEMBL3599903 | 0.81 | REN (0.49) | RENHTTSMN1; SMN2 | |
| SCHEMBL14987993 | 0.81 | REN (0.49) | RENHTTSMN1; SMN2 | |
| SCHEMBL1867207 | 0.76 | CTSS (0.54) | ALDH1A1RENSMN1; SMN2 | |
| SCHEMBL2158933 | 0.74 | KDM4E (0.58) | KDM4EALDH1A1LMNAHTTHPGD | |
| SCHEMBL8241092 | 0.73 | CTSS (0.40) | HTTUSP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21640494 | 0.68 | USP2 (0.54) | KDM4EALDH1A1LMNAHTTHPGD | |
| SCHEMBL5509776 | 0.68 | HTT (0.45) | RENHTTSMN1; SMN2 | |
| SCHEMBL3607729 | 0.68 | USP2 (0.40) | ALDH1A1HTTHPGDUSP2SMN1; SMN2 | |
| SCHEMBL5505421 | 0.68 | HTT (0.45) | RENHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | KDM4E 2286/4885ALDH1A1 1416/4885LMNA 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.